⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 23, 2026Life Sciences

Prime-edited isogenic hiPSC-cardiomyocytes model short QT syndrome type 3 and drug responses

Saltanat Zhazykbayeva Nazha Hamdani Ibrahim El‐Battrawy

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhazykbayeva et al. (2026) studied this question.

synapsesocial.com/papers/6ad115e000741cc3fba7daea https://doi.org/10.1016/j.lfs.2026.124602

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Differences in Short QT Syndrome Subtypes: A Systematic Literature Review and Pooled Analysissystematic_review · 2020 · 19 citations
2Idiopathic Short QT Interval:A New Clinical Syndrome?case_series · 2000 · 671 citations
3The Short QT Syndromesystematic_review · 2011 · 319 citations
4Preclinical short QT syndrome models: studying the phenotype and drug-screeningreview · 2021 · 20 citations
5Animal Models to Study Cardiac Arrhythmiasreview · 2022 · 90 citations

More related papers

In silico investigation of the short QT syndrome, using human ventricle models incorporating electromechanical coupling2013
Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes as Models for Cardiac Channelopathies2018
Modeling Short QT Syndrome Using Human‐Induced Pluripotent Stem Cell–Derived Cardiomyocytes2018

More from Life Sciences

Targeting the Src/OXPHOS axis to attenuate myocardial oxidative stress injury in type 2 diabetesThu,
Loss of bves leads to cardiac contractile dysfunction and myocardial mitochondrial damage in zebrafishSat,